Education
About Us
Working with TipRanks
Follow Us
OZEM - ETF AI Analysis
Top Page
Roundhill GLP-1 & Weight Loss ETF (OZEM)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Sector Focus
The ETF is heavily weighted in the health care sector, which has shown resilience and growth potential in the weight loss and GLP-1 drug space.
Healthy Performance Trends
The fund has delivered steady gains year-to-date and over the past three months, indicating positive momentum.
Global Diversification
While primarily focused on U.S. companies, the ETF includes exposure to international markets like Hong Kong, Japan, and Switzerland, adding geographic balance.
Negative Factors
Underperforming Key Holdings
Several top holdings, including Novo Nordisk and Viking Therapeutics, have lagged in year-to-date performance, which could weigh on overall returns.
High Sector Concentration
With over 85% of the portfolio in health care, the fund is highly exposed to risks specific to this sector.
Moderate Expense Ratio
The ETF’s expense ratio is higher than some low-cost alternatives, which could reduce net returns for long-term investors.
OZEM vs. SPDR S&P 500 ETF (SPY)
AUM50.08M
RegionGlobal
Expense Ratio0.59%
Beta0.80
IssuerRoundhill
Inception DateMay 21, 2024
Dividend Yield1.15%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume28,993
30 Day Avg. Volume19,418
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.63Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OZEM Summary
The Roundhill GLP-1 & Weight Loss ETF (Ticker: OZEM) focuses on companies in the healthcare sector, particularly those involved in pharmaceuticals, biotechnology, and life sciences. It targets firms developing innovative treatments for obesity and metabolic disorders, including well-known names like Novo Nordisk and Eli Lilly. This ETF could appeal to investors looking for growth opportunities in the health and wellness industry, which is becoming increasingly important globally. However, new investors should be aware that the ETF is heavily concentrated in healthcare, meaning its performance could be impacted by changes in that sector or regulatory challenges.
How much will it cost me?The Roundhill GLP-1 & Weight Loss ETF (OZEM) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a niche sector like pharmaceuticals and biotechnology, which requires more research and specialized management.
What would affect this ETF?The Roundhill GLP-1 & Weight Loss ETF could benefit from growing global demand for innovative health solutions, particularly in obesity and metabolic disorder treatments, as well as advancements in biotechnology and pharmaceuticals led by top holdings like Novo Nordisk and Eli Lilly. However, potential risks include regulatory hurdles, competition in the weight management sector, and broader economic challenges that may impact healthcare spending or innovation funding. Global exposure also means the ETF could be affected by geopolitical events or currency fluctuations.
OZEM Top 10 Holdings
The Roundhill GLP-1 & Weight Loss ETF is heavily concentrated in the healthcare sector, with Eli Lilly and Novo Nordisk leading the charge in weight management innovation. Eli Lilly’s steady rise has been a key driver of the fund’s performance, while Novo Nordisk has faced mixed results, weighed down by market share challenges. Structure Therapeutics is a rising star, delivering strong momentum despite its speculative nature. Roche and Viking Therapeutics provide steady contributions, though valuation concerns linger. With a global focus, this ETF is riding the wave of groundbreaking advancements in obesity treatments.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 22.02% | $11.03M | $264.24B | -26.26% | 73 Outperform | |
| Eli Lilly & Co | 15.33% | $7.68M | $1.01T | 45.12% | 72 Outperform | |
| Roche Holding AG | 4.16% | $2.08M | CHF272.24B | 48.53% | 73 Outperform | |
| Pfizer | 3.96% | $1.98M | $144.87B | -4.32% | 74 Outperform | |
| ― | 3.92% | $1.96M | ― | ― | ― | |
| Structure Therapeutics, Inc. Sponsored ADR | 3.89% | $1.95M | $4.16B | 175.68% | 31 Underperform | |
| Chugai Pharmaceutical Co | 3.88% | $1.94M | ¥13.85T | 18.05% | 74 Outperform | |
| Viking Therapeutics | 3.88% | $1.94M | $3.62B | -6.40% | 53 Neutral | |
| Ascletis Pharma, Inc. | 3.61% | $1.81M | HK$12.49B | 291.82% | 54 Neutral | |
| Innovent Biologics | 3.56% | $1.78M | HK$154.90B | 172.27% | 61 Neutral |
OZEM Technical Analysis
Positive
―
Price Trends
32.78
Positive
29.82
Positive
27.09
Positive
Market Momentum
0.79
Positive
67.91
Neutral
68.08
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.59, equal to the 50-day MA of 32.78, and equal to the 200-day MA of 27.09, indicating a bullish trend. The MACD of 0.79 indicates Positive momentum. The RSI at 67.91 is Neutral, neither overbought nor oversold. The STOCH value of 68.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OZEM.
OZEM Peer Comparison
Comparison Results
Performance Comparison
OZEM
Roundhill GLP-1 & Weight Loss ETF
35.62
12.52
54.20%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents